close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

225.54 +6.47 (+2.95%)
Streaming Delayed Price Updated: 3:58 PM EDT, Sep 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley... 
Via MarketBeat
News headline image
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to... 
Via MarketBeat
Thursday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating ↗
Via Chartmill
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove... 
Via StockStory
Topics Artificial Intelligence
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how therapeutics stocks fa... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 pe... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q2 2026 Earnings Call Transcript ↗
Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter. 
Via The Motley Fool
Topics Earnings
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call
Biogen’s second quarter witnessed a positive market response, buoyed by notable revenue growth and a significant beat on non-GAAP profit relative to analysts... 
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion... 
Via StockStory
News headline image
Why Biogen Stock Topped the Market Today ↗
The company published its second-quarter results on Wednesday morning. 
Via The Motley Fool
News headline image
Biogen Q2 Earnings Call Highlights ↗
Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results.... 
Via MarketBeat
Topics Earnings
News headline image
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP prof... 
Via StockStory
News headline image
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for. Biogen beat analysts’ revenue exp... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks We Steer Clear Of
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
3 Reasons to Avoid BIIB and 1 Stock to Buy Instead
Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to... 
Via StockStory
Topics Stocks
Discover which S&P500 stocks are making waves on Tuesday. ↗
Via Chartmill
News headline image
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss ↗
Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary... 
Via MarketBeat
These S&P500 stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
1 Mid-Cap Stock to Target This Week and 2 We Find Risky
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions ↗
Energy names help cushion the Dow as oil jumps on U.S.–Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026. 
Via The Motley Fool
Topics Economy Stocks
News headline image
1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.